Clinical trials
Liver Cell Carcinoma clinical trials
Below are recruiting liver cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 445 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07125755RecruitingPhase 3
Comparing Chemo plus Radiation vs. Radiation Alone for Head and Neck Cancer
This trial tests whether adding chemotherapy to radiation therapy after surgery can help prevent head and neck cancer from coming back. It is for people who have certain risk factors after their surgery but no signs of cancer spread.
Guangzhou, GuangdongAges 18–70 - NCT07425054RecruitingPhase 2
Chemoradiation with or without immunotherapy for anal cancer
This trial tests whether adding an immunotherapy drug (retifanlimab) to standard chemoradiation improves outcomes for people with locally advanced anal cancer. The treatment is adjusted based on HPV DNA levels in your blood.
Cleveland, OhioAges 18 years+ - NCT07657325Recruiting
Toripalimab for high-risk kidney cancer that has been removed
This trial tests whether the drug toripalimab can prevent kidney cancer from coming back in people who have had their kidney and any visible metastases surgically removed. It focuses on patients with high-risk features or who had some metastatic spots taken out completely.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT04977453RecruitingPhase 1/Phase 2
Study drug GI-101 alone or with immune or blood-pressure meds
This early-phase study tests GI-101 in people with advanced solid cancers. It may be given alone or combined with pembrolizumab or lenvatinib to see how safe it is and whether it can shrink tumors.
New York, New YorkAges 18 years+ - NCT03215719RecruitingPhase 2
De-escalating treatment for HPV-positive throat cancer with low-risk signals
This Phase 2 trial tests whether people with HPV-positive oropharyngeal (throat) cancer who look “lower risk” can safely receive less intensive treatment. It uses HPV blood test results and cancer staging scans to guide whether treatment can be de-escalated.
New York, New YorkAges 18 years+ - NCT06362369RecruitingPhase 1/Phase 2
Oral 7HP349 with immunotherapy for advanced solid tumors
This trial tests an experimental oral drug (7HP349) combined with two immunotherapy drugs (ipilimumab and nivolumab) for people with advanced solid tumors. It aims to see if the combination is safe and effective in shrinking tumors.
Aurora, ColoradoAges 18 years+ - NCT05231122RecruitingPhase 2
Pembrolizumab and bevacizumab for recurrent ovarian cancer
This trial studies whether adding pembrolizumab to bevacizumab (and sometimes an anti-CD40 drug) can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also looks at whether the treatment can shrink tumors and keep them from growing for longer.
Buffalo, New YorkAges 18 years+ - NCT06543576RecruitingPhase 1/Phase 2
Radiation and drug therapy for stage IVB cervical cancer
This trial tests combining external and internal radiation with chemotherapy and immunotherapy for stage IVB cervical cancer that has not been treated before. The goal is to see if this approach can help shrink tumors and improve outcomes.
Los Angeles, CaliforniaAges 18 years+ - NCT07110038RecruitingPhase 2
Study of Enfortumab Vedotin Plus Avelumab for Advanced Penile Cancer
This trial tests a combination of two drugs (enfortumab vedotin and avelumab) as a first treatment for men with advanced or metastatic penile cancer that cannot be removed by surgery. The goal is to see if this new combination can shrink tumors and improve outcomes.
DresdenAges 18 years+ - NCT03895359RecruitingPhase 3
Chemo plus targeted radiation versus chemo alone for liver cancer
This trial compares two treatments for liver cancer that can’t be removed with surgery: chemo through the liver (TACE) alone versus TACE plus a precise radiation treatment (SBRT). It may help people whose cancer stays in the liver but can’t be operated on, by testing whether adding focused radiation improves outcomes.
London, OntarioAges 18 years+ - NCT04444869RecruitingPhase 2
Lower-dose radiation with chemotherapy for low-risk HPV throat cancer
This trial tests whether a less intense (lower-dose) radiation plan, combined with chemotherapy, can control HPV-positive oropharyngeal (throat) cancer with fewer side effects. It targets people considered “low-risk” based on tumor size and lymph node involvement.
Columbia, MissouriAges 18 years+ - NCT06783348RecruitingPhase 2
Radioactive treatment for advanced kidney cancer
This trial tests a radioactive treatment (called radiopharmaceutical) that targets a protein called PSMA on kidney cancer cells. It is for people with advanced clear cell kidney cancer that has already been treated with immunotherapy and targeted therapy.
CaenAges 18–100 - NCT07275073RecruitingPhase 1
JMT106 for advanced solid tumors
This trial is testing a new medicine called JMT106 for people with advanced solid tumors (cancers that have spread or can't be removed). It's for patients whose cancer has not responded to or can't use other treatments, and who have not had a therapy targeting a specific protein (GPC3) before.
ZhejiangAges 18 years+ - NCT07386158RecruitingPhase 2
Immunotherapy before surgery for clear cell kidney cancer
This trial tests whether giving pucotenlimab (an immunotherapy drug) with vorolanib (a targeted therapy) before surgery helps shrink clear cell kidney tumors and makes kidney-sparing surgery safer. It is for people with localized, non-metastatic disease where the tumor is difficult to remove with partial nephrectomy.
Guangzhou, Other (Non U.s.)Ages 18–85 - NCT07389629RecruitingPhase 2
Combination therapy before surgery for kidney cancer
This trial tests a new drug combination given before surgery for kidney cancer that is early stage but hard to operate on. The goal is to shrink the tumor and make surgery easier.
GuangzhouAges 18–80 - NCT05738980Recruiting
Reduce liver cancer return after surgery using anti–TIM-3
This trial studies whether blocking TIM-3 (an immune “brake”) can help stop hepatocellular carcinoma (liver cancer) from coming back after a curative surgery. It may help by improving your immune system’s ability to find and control remaining cancer cells.
Beijing, Beijing MunicipalityAges 18–75 - NCT04969354RecruitingPhase 1
CAIX-targeted CAR-T therapy for advanced kidney cancer
This early-phase study tests a lab-made immune treatment (CAIX-targeted CAR-T cells) for advanced kidney cancer that has not gone away with standard targeted therapy or immunotherapy. If eligible, the goal is to see if the treatment can safely shrink the cancer and improve outcomes.
Xuzhou, JiangsuAges 18–70 - NCT05323201RecruitingPhase 1/Phase 2
B7H3 CAR-T therapy for advanced liver cancer
This trial tests an immune therapy made from your own blood cells (CAR-T) to treat advanced, unresectable liver cancer. It’s designed for people whose tumor has a specific marker called B7H3 and who meet blood, organ, and safety requirements.
Xuzhou, JiangsuAges 18–70 - NCT07181720RecruitingPhase 1
CD70-targeted CAR-T therapy for advanced solid tumors
This trial tests a new treatment called CAR-T that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments.
Hefei, AnhuiAges 18 years+ - NCT05691465RecruitingPhase 2
Radiation drug for metastatic prostate cancer with neuroendocrine cells
This Phase 2 study tests whether a radioactive medicine called lutetium Lu 177 dotatate is safe and effective for metastatic prostate cancer that has neuroendocrine features. It also checks whether patients’ scans show the cancer absorbs the drug (a requirement to start treatment).
Duarte, CaliforniaAges 18 years+ - NCT06671275Enrolling by invitationPhase 1
Testing CUD005 Injection for Advanced Liver Cirrhosis
This study tests an injection called CUD005 for people with advanced liver cirrhosis that is causing complications. The goal is to see if it is safe and can help improve liver function.
Hefei, AnhuiAges 18–75 - NCT05563766RecruitingPhase 2
Itraconazole added for treatable esophageal cancer before surgery
This study tests whether adding itraconazole (an anti-fungal medicine) to standard chemo-radiation before surgery increases the chance of complete tumor response. It’s for people with esophageal (or GE junction) cancer that can be removed with curative surgery after treatment.
Palo Alto, CaliforniaAges 18 years+ - NCT05583708RecruitingPhase 2
Trial tests targeted radiation plus immunotherapy after anti–PD-1 failure
This Phase 2 trial studies whether peptide receptor radionuclide therapy (targeted radiation) combined with immunotherapy (pembrolizumab) can shrink Merkel cell cancer after it has grown despite anti–PD-1/L1 treatment. It may help people whose cancer has specific receptors that make them eligible for the targeted radiation.
Iowa City, IowaAges 18 years+ - NCT06534762RecruitingPhase 2
Miraberon for advanced solid tumors (first treatment)
This study tests a drug called Miraberon for people with advanced solid tumors that have not yet been treated with chemotherapy or other cancer drugs. The goal is to see if Miraberon can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–65
Hear when a new Liver Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for liver cell carcinoma?
- Yes. Clin2 currently lists 445 recruiting liver cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a liver cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a liver cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.